secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medline Inc. (MDLN)
CIK:        0002046386
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0002046386-26-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medline Q4 net income down 37.7% to $180M; FY25 EBITDA up 3.2%; guides FY26 organic sales growth 8-9%
--------------------------------------------------------------------------------

- Q4 net sales $7.8B (+14.8% YoY); net income $180M (-37.7%); Adj. EBITDA $805M (flat).
- FY25 net sales $28.4B (+11.5%); net income $1.2B (-3.6%); Adj. EBITDA $3.5B (+3.2%).
- FY25 organic sales growth 10.5%; net cash from ops $1.7B; Free Cash Flow $1.3B.
- FY26 guidance: organic sales growth 8-9%; Adj. EBITDA $3.5-3.6B.
- Margins pressured by tariffs and higher costs; $2.4B in new customer signings in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2046386/000204638626000007/0002046386-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2046386/000204638626000007/mdln-20260225.htm
  HTML page:      https://secwatch.observer/filing/0002046386-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer